Jeffrey Mindel, MD
Endocrinology, Diabetes & Metabolism · Timonium, MDNPI 1821133091
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,172 of the $6,994 with a category attached, or 88.2%. It is spread thinly across 50 manufacturers, the largest accounting for just 9.0% — the pattern of someone who eats at a lot of different presentations.
Across 312 payments — averaging $22.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$633
- Amgen$563
- Sanofi-aventis U.S. LLC$452
- Novo Nordisk$389
- AbbVie$368
- Radius Health, Inc.$345
- plus $4K from 44 others
What the payments were for
- Consulting fees$3755%
- Speaking & faculty fees$4476%
- Food & beverage$6,17288%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,994 in reported general payments places this provider in the 75th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 178 | $287,339 |
| OzempicSemaglutide | 99 | $208,353 |
| JardianceEmpagliflozin | 49 | $69,827 |
| JanuviaSitagliptin Phosphate | 50 | $66,656 |
| Tresiba Flextouch U-200Insulin Degludec | 53 | $62,305 |
| TymlosAbaloparatide | 16 | $61,044 |
| TrulicityDulaglutide | 41 | $57,849 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 91 | $56,863 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 31 | $52,515 |
| FarxigaDapagliflozin Propanediol | 48 | $45,903 |
| RybelsusSemaglutide | 31 | $39,130 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $37,881 |
| Humalog Kwikpen U-200Insulin Lispro | 17 | $36,610 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 19 | $25,866 |
| Novolog FlexpenInsulin Aspart | 43 | $23,831 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $256 | $352,157232 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $389 | $253,010149 claims |
| Boehringer IngelheimJardiance | $126 | $69,82749 claims |
| MerckJanuvia | $27 | $66,65650 claims |
| Radius Health, Inc.Tymlos | $345 | $61,04416 claims |
| AstraZenecaFarxiga | $321 | $45,90348 claims |
| AbbVieSynthroid | $368 | $11,697165 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $238 | $4,998389 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Timonium
- Joanna TyzackTimonium$7K
- Ruth HorowitzTimonium$7K
- Ashley DavidsonTimonium$6K
- Meena KhanTimonium$5K
- Daniel GozziSuitland$1.2M
- Martin SarkarFrederick$1.1M
- Nicholas ArgentoLaurel$1.1M
- Romeu AzevedoCamp Springs$987K
- David BrownRockville$497K
- Philip LevinBaltimore$489K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.